CONTEXT: Selective adenomectomy via transsphenoidal surgery induces remission of Cushing's disease (CD) in most patients. Although an undetectable postoperative serum cortisol (<2 μg/dl) has been advocated as an index of remission, there is no consensus on predictors of recurrence. OBJECTIVE: We hypothesized that patients with subnormal cortisol (2-4.9 μg/dl) might achieve long-term remission and that postoperative responses to CRH might predict recurrence. DESIGN, SETTING, AND PARTICIPANTS: We prospectively studied CD patients with initial remission after adenomectomy or hemihypophysectomy (n = 14). Long-term recurrence (n = 39) or remission (n = 293) was assigned by laboratory results, glucocorticoid dependence, or patient survey at a mean of 10.6 yr after surgery. INTERVENTION AND MAIN OUTCOME MEASURES: Postoperatively, morning cortisol was measured on d 3-5, and cortisol and ACTH responses to ovine CRH were assessed around d 10. RESULTS: Follow-up duration was median 11 yr (range 1-22.8 yr). Fewer patients achieved a cortisol nadir below 2 μg/dl (87%) than below 5 μg/dl (98%), yet recurrence rates were similar (<2 μg/dl, 9.5%; <5 μg/dl, 10.4%; 2-4.9 μg/dl, 20%; not significant). CRH-stimulated cortisol (P < 0.002) and ACTH (P = 0.04) values were higher for the recurrence than the remission group. However, no basal or stimulated ACTH or serum or urine cortisol cutoff value predicted all who later recurred. CONCLUSIONS: A postoperative cortisol below 2 μg/dl predicts long-term remission after transsphenoidal surgery in CD. Remission in those with intermediate d 3-5 postoperative cortisol values (2-4.9 μg/dl) suggests that these patients do not require immediate reoperation. However, because no single cortisol cutoff value excludes all patients with recurrence, all require long-term clinical follow-up.
CONTEXT: Selective adenomectomy via transsphenoidal surgery induces remission of Cushing's disease (CD) in most patients. Although an undetectable postoperative serum cortisol (<2 μg/dl) has been advocated as an index of remission, there is no consensus on predictors of recurrence. OBJECTIVE: We hypothesized that patients with subnormal cortisol (2-4.9 μg/dl) might achieve long-term remission and that postoperative responses to CRH might predict recurrence. DESIGN, SETTING, AND PARTICIPANTS: We prospectively studied CDpatients with initial remission after adenomectomy or hemihypophysectomy (n = 14). Long-term recurrence (n = 39) or remission (n = 293) was assigned by laboratory results, glucocorticoid dependence, or patient survey at a mean of 10.6 yr after surgery. INTERVENTION AND MAIN OUTCOME MEASURES: Postoperatively, morning cortisol was measured on d 3-5, and cortisol and ACTH responses to ovine CRH were assessed around d 10. RESULTS: Follow-up duration was median 11 yr (range 1-22.8 yr). Fewer patients achieved a cortisol nadir below 2 μg/dl (87%) than below 5 μg/dl (98%), yet recurrence rates were similar (<2 μg/dl, 9.5%; <5 μg/dl, 10.4%; 2-4.9 μg/dl, 20%; not significant). CRH-stimulated cortisol (P < 0.002) and ACTH (P = 0.04) values were higher for the recurrence than the remission group. However, no basal or stimulated ACTH or serum or urine cortisol cutoff value predicted all who later recurred. CONCLUSIONS: A postoperative cortisol below 2 μg/dl predicts long-term remission after transsphenoidal surgery in CD. Remission in those with intermediate d 3-5 postoperative cortisol values (2-4.9 μg/dl) suggests that these patients do not require immediate reoperation. However, because no single cortisol cutoff value excludes all patients with recurrence, all require long-term clinical follow-up.
Authors: Felice Esposito; Joshua R Dusick; Pejman Cohan; Parham Moftakhar; David McArthur; Christina Wang; Ronald S Swerdloff; Daniel F Kelly Journal: J Clin Endocrinol Metab Date: 2005-10-18 Impact factor: 5.958
Authors: B Swearingen; B M Biller; F G Barker; L Katznelson; S Grinspoon; A Klibanski; N T Zervas Journal: Ann Intern Med Date: 1999-05-18 Impact factor: 25.391
Authors: Gary D Hammer; J Blake Tyrrell; Kathleen R Lamborn; Carol B Applebury; Elizabeth T Hannegan; Scott Bell; Riva Rahl; Amy Lu; Charles B Wilson Journal: J Clin Endocrinol Metab Date: 2004-12 Impact factor: 5.958
Authors: Chirag G Patil; Daniel M Prevedello; Shivanand P Lad; Mary Lee Vance; Michael O Thorner; Laurence Katznelson; Edward R Laws Journal: J Clin Endocrinol Metab Date: 2007-12-04 Impact factor: 5.958
Authors: Philip C Johnston; Laurence Kennedy; Amir H Hamrahian; Zahrae Sandouk; James Bena; Betul Hatipoglu; Robert J Weil Journal: Pituitary Date: 2017-08 Impact factor: 4.107
Authors: Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee Journal: Endocrine Date: 2018-11-24 Impact factor: 3.633
Authors: Sandeep Kharb; Abhay Gundgurthi; Aditi Pandit; M K Garg; K S Brar; Amandeep Singh; H C Pathak Journal: Med J Armed Forces India Date: 2012-07-17
Authors: Nadia Hameed; Chris G Yedinak; Jessica Brzana; Sakir H Gultekin; Nicholas D Coppa; Aclan Dogan; Johnny B Delashaw; Maria Fleseriu Journal: Pituitary Date: 2013-12 Impact factor: 4.107
Authors: Russell R Lonser; Joshua J Wind; Lynnette K Nieman; Robert J Weil; Hetty L DeVroom; Edward H Oldfield Journal: J Clin Endocrinol Metab Date: 2013-01-31 Impact factor: 5.958